Risk factors associated with Barrett's epithelial dysplasia

World Journal of Gastroenterology

Volumn 20, Issue 15, 2014, Pages 4353-4361

  Fujita, Mikiko ^a   Nakamura, Yuri ^a   Kasashima, Saeko ^a   Furukawa, Maiko ^a   Misaka, Ryoichi ^a   Nagahara, Hikaru ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Barrett's esophagus; Dysplasia; Helicobacter pylori; p53; Risk factors

Indexed keywords

ADULT; ANTHROPOMETRY; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; CHEMICAL ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; ENDOSCOPY; EPITHELIUM DYSPLASIA; FEMALE; GLUCOSE METABOLISM; HELICOBACTER INFECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENCE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; PROTEIN EXPRESSION; RISK FACTOR; WAIST CIRCUMFERENCE; AGED; BIOPSY; BLOOD PRESSURE; BODY WEIGHT; COMPLICATION; ESOPHAGUS DISEASE; JAPAN; METABOLISM; PATHOLOGY; RISK; STOMACH MUCOSA;

PROTEIN P53; TP53 PROTEIN, HUMAN;

AGED; ANTHROPOMETRY; BARRETT ESOPHAGUS; BIOPSY; BLOOD PRESSURE; BODY MASS INDEX; BODY WEIGHT; ENDOSCOPY; ESOPHAGEAL DISEASES; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HUMANS; JAPAN; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; PREVALENCE; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84898868328     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i15.4353     Document Type: Article

References (50)

1. Milind R, Attwood SE. Natural history of Barrett's esophagus. World J Gastroenterol 2012; 18: 3483-3491 [PMID: 22826612 DOI: 10.3748/wjg.v18.i27.3483]
2. Wiseman EF, Ang YS. Risk factors for neoplastic progression in Barrett's esophagus. World J Gastroenterol 2011; 17: 3672-3683 [PMID: 21990948 DOI: 10.3748/wjg.v17.i32.3672]
3. den Hoed CM, van Blankenstein M, Dees J, Kuipers EJ. The minimal incubation period from the onset of Barrett's oesophagus to symptomatic adenocarcinoma. Br J Cancer 2011; 105: 200-205 [PMID: 21673678 DOI: 10.1038/bjc.2011.214]
4. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ, Agréus L. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 2005; 129: 1825-1831 [PMID: 16344051 DOI: 10.1053/j.gastro.2005.08.053]
5. Curvers WL, ten Kate FJ, Krishnadath KK, Visser M, Elzer B, Baak LC, Bohmer C, Mallant-Hent RC, van Oijen A, Naber AH, Scholten P, Busch OR, Blaauwgeers HG, Meijer GA, Bergman JJ. Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010; 105: 1523-1530 [PMID: 20461069 DOI: 10.1038/ajg.2010.171]
6. Wani S, Puli SR, Shaheen NJ, Westhoff B, Slehria S, Bansal A, Rastogi A, Sayana H, Sharma P. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009; 104: 502-513 [PMID: 19174812 DOI: 10.1038/ajg.2008.31]
7. Westhoff B, Brotze S, Weston A, McElhinney C, Cherian R, Mayo MS, Smith HJ, Sharma P. The frequency of Barrett's esophagus in high-risk patients with chronic GERD. Gastrointest Endosc 2005; 61: 226-231 [PMID: 15729230 DOI: 10.1016/ S0016-5107(04)02589-1]
8. Eloubeidi MA, Provenzale D. Clinical and demographic predictors of Barrett's esophagus among patients with gastroesophageal reflux disease: a multivariable analysis in veterans. J Clin Gastroenterol 2001; 33: 306-309 [PMID: 11588545 DOI: 10.1097/00004836-200110000-00010]
9. Johansson J, Håkansson HO, Mellblom L, Kempas A, Johansson KE, Granath F, Nyrén O. Risk factors for Barrett's oesophagus: a population-based approach. Scand J Gastroenterol 2007; 42: 148-156 [PMID: 17327933 DOI: 10.1080/003655 20600881037]
10. Smith KJ, O'Brien SM, Smithers BM, Gotley DC, Webb PM, Green AC, Whiteman DC. Interactions among smoking, obesity, and symptoms of acid reflux in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2005; 14: 2481-2486 [PMID: 16284367 DOI: 10.1158/1055-9965.EPI-05-0370]
11. Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130: 883-890 [PMID: 10375336 DOI: 10.7326/0003-4819-130-11-199906010-00003]
12. El-Serag HB, Kvapil P, Hacken-Bitar J, Kramer JR. Abdominal obesity and the risk of Barrett's esophagus. Am J Gastroenterol 2005; 100: 2151-2156 [PMID: 16181362 DOI: 10.1111/ j.1572-0241.2005.00251.x]
13. Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Quesenberry C, Rumore GJ, Buffler PA. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology 2007; 133: 34-41; quiz 311 [PMID: 17631128 DOI: 10.1053/j.gastro.2007.04.046]
14. Edelstein ZR, Farrow DC, Bronner MP, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett's esophagus. Gastroenterology 2007; 133: 403-411 [PMID: 17681161 DOI: 10.1053/ j.gastro.2007.05.026]
15. Bu X, Ma Y, Der R, Demeester T, Bernstein L, Chandrasoma PT. Body mass index is associated with Barrett esophagus and cardiac mucosal metaplasia. Dig Dis Sci 2006; 51: 1589-1594 [PMID: 16927134 DOI: 10.1007/s10620-006-9118-0]
16. Ryan AM, Healy LA, Power DG, Byrne M, Murphy S, Byrne PJ, Kelleher D, Reynolds JV. Barrett esophagus: prevalence of central adiposity, metabolic syndrome, and a proinflammatory state. Ann Surg 2008; 247: 909-915 [PMID: 18520215 DOI: 10.1097/SLA.0b013e3181612cac]
17. Wood RK, Yang YX. Barrett's esophagus in 2008: an update. Keio J Med 2008; 57: 132-138 [PMID: 18854665 DOI: 10.2302/ kjm.57.132]
18. Ye W, Held M, Lagergren J, Engstrand L, Blot WJ, McLaughlin JK, Nyrén O. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J Natl Cancer Inst 2004; 96: 388-396 [PMID: 14996860 DOI: 10.1093/jnci/djh057]
19. McColl KE. Review article: Helicobacter pylori and gastrooesophageal reflux disease--the European perspective. Aliment Pharmacol Ther 2004; 20 Suppl 8: 36-39 [PMID: 15575871 DOI: 10.1111/j.1365-2036.2004.02227.x]
20. Weston AP, Badr AS, Topalovski M, Cherian R, Dixon A, Hassanein RS. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma. Am J Gastroenterol 2000; 95: 387-394 [PMID: 10685740 DOI: 10.1111/j.1572-0241.2000.01758.x]
21. Wang C, Yuan Y, Hunt RH. Helicobacter pylori infection and Barrett's esophagus: a systematic review and metaanalysis. Am J Gastroenterol 2009; 104: 492-500; quiz 491, 501 [PMID: 19174811 DOI: 10.1038/ajg.2008.37]
22. Corley DA, Kubo A, Levin TR, Block G, Habel L, Zhao W, Leighton P, Rumore G, Quesenberry C, Buffler P, Parsonnet J. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut 2008; 57: 727-733 [PMID: 17895354 DOI: 10.1136/gut.2007.132068]
23. Rokkas T, Pistiolas D, Sechopoulos P, Robotis I, Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1413-1417, 1417. e1-2 [PMID: 17997357]
24. Chow WH, Blaser MJ, Blot WJ, Gammon MD, Vaughan TL, Risch HA, Perez-Perez GI, Schoenberg JB, Stanford JL, Rotterdam H, West AB, Fraumeni JF. An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res 1998; 58: 588-590 [PMID: 9485003]
25. Wu AH, Crabtree JE, Bernstein L, Hawtin P, Cockburn M, Tseng CC, Forman D. Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer 2003; 103: 815-821 [PMID: 12516104 DOI: 10.1002/ijc.10887]
26. Huang JQ, Zheng GF, Sumanac K, Irvine EJ, Hunt RH. Metaanalysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003; 125: 1636-1644 [PMID: 14724815 DOI: 10.1053/j.gastro.2003.08.033]
27. Hongo M. Review article: Barrett's oesophagus and carcinoma in Japan. Aliment Pharmacol Ther 2004; 20 Suppl 8: 50-54 [PMID: 15575874 DOI: 10.1111/j.1365-2036.2004.02230.x]
28. Okita K, Amano Y, Takahashi Y, Mishima Y, Moriyama N, Ishimura N, Ishihara S, Kinoshita Y. Barrett's esophagus in Japanese patients: its prevalence, form, and elongation. J Gastroenterol 2008; 43: 928-934 [PMID: 19107336 DOI: 10.1007/ s00535-008-2261-y]
29. Moons LM, Bax DA, Kuipers EJ, Van Dekken H, Haringsma J, Van Vliet AH, Siersema PD, Kusters JG. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J Clin Pathol 2004; 57: 1063-1068 [PMID: 15452161 DOI: 10.1136/jcp.2003.015727]
30. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103: 788-797 [PMID: 18341497 DOI: 10.1111/j.1572-0241.2008.01835.x]
31. Nobukawa B, Abraham SC, Gill J, Heitmiller RF, Wu TT. Clinicopathologic and molecular analysis of high-grade dysplasia and early adenocarcinoma in short-versus longsegment Barrett esophagus. Hum Pathol 2001; 32: 447-454 [PMID: 11331963 DOI: 10.1053/hupa.2001.23513]
32. Vahabzadeh B, Seetharam AB, Cook MB, Wani S, Rastogi A, Bansal A, Early DS, Sharma P. Validation of the Prague C & amp; M criteria for the endoscopic grading of Barrett's esophagus by gastroenterology trainees: a multicenter study. Gastrointest Endosc 2012; 75: 236-241 [PMID: 22248595 DOI: 10.1016/j.gie.2011.09.017]
33. Goh KL. Gastroesophageal reflux disease in Asia: A historical perspective and present challenges. J Gastroenterol Hepatol 2011; 26 Suppl 1: 2-10 [PMID: 21199509 DOI: 10.1111/ j.1440-1746.2010.06534.x]
34. Takubo K, Aida J, Sawabe M, Arai T, Kato H, Pech O, Arima M. The normal anatomy around the oesophagogastric junction: a histopathologic view and its correlation with endoscopy. Best Pract Res Clin Gastroenterol 2008; 22: 569-583 [PMID: 18656817 DOI: 10.1016/j.bpg.2008.02.004]
35. Takubo K, Vieth M, Aida J, Sawabe M, Kumagai Y, Hoshihara Y, Arai T. Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. Digestion 2009; 80: 248-257 [PMID: 19828957 DOI: 10.1159/000235923]
36. Schlemper RJ, Riddell RH, Kato Y, Borchard F, Cooper HS, Dawsey SM, Dixon MF, Fenoglio-Preiser CM, Fléjou JF, Geboes K, Hattori T, Hirota T, Itabashi M, Iwafuchi M, Iwashita A, Kim YI, Kirchner T, Klimpfinger M, Koike M, Lauwers GY, Lewin KJ, Oberhuber G, Offner F, Price AB, Rubio CA, Shimizu M, Shimoda T, Sipponen P, Solcia E, Stolte M, Watanabe H, Yamabe H. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-255 [PMID: 10896917 DOI: 10.1136/gut.47.2.251]
37. Keswani RN, Noffsinger A, Waxman I, Bissonnette M. Clinical use of p53 in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2006; 15: 1243-1249 [PMID: 16835318 DOI: 10.1158/1055-9965.EPI-06-0010]
38. Shimamoto K. [Metabolic syndrome: epidemiology]. Nihon Naika Gakkai Zasshi 2004; 93: 642-647 [PMID: 15174707 DOI: 10.2169/naika.93.642]
39. Clark GW. Effect of Helicobacter pylori infection in Barrett' s esophagus and the genesis of esophageal adenocarcinoma. World J Surg 2003; 27: 994-998 [PMID: 14560364 DOI: 10.1007/s00268-003-7051-3]
40. Thrift AP, Pandeya N, Smith KJ, Green AC, Hayward NK, Webb PM, Whiteman DC. Helicobacter pylori infection and the risks of Barrett's oesophagus: a population-based case-control study. Int J Cancer 2012; 130: 2407-2416 [PMID: 21681741 DOI: 10.1002/ijc.26242]
41. Neshat K, Sanchez CA, Galipeau PC, Blount PL, Levine DS, Joslyn G, Reid BJ. p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 1994; 106: 1589-1595 [PMID: 8194706]
42. Bian YS, Osterheld MC, Bosman FT, Benhattar J, Fontolliet C. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol 2001; 14: 397-403 [PMID: 11353048 DOI: 10.1038/modpathol.3880324]
43. Novotna K, Trkova M, Pazdro A, Smejkal M, Soukupova A, Kodetova D, Smejkal P, Sedlacek Z. TP53 gene mutations are rare in nondysplastic Barrett's esophagus. Dig Dis Sci 2006; 51: 110-113 [PMID: 16416221 DOI: 10.1007/s10620-006-3093-3]
44. Ramel S, Reid BJ, Sanchez CA, Blount PL, Levine DS, Neshat K, Haggitt RC, Dean PJ, Thor K, Rabinovitch PS. Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. Gastroenterology 1992; 102: 1220-1228 [PMID: 1551529]
45. Galipeau PC, Cowan DS, Sanchez CA, Barrett MT, Emond MJ, Levine DS, Rabinovitch PS, Reid BJ. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci USA 1996; 93: 7081-7084 [PMID: 8692948 DOI: 10.1073/pnas.93.14.7081]
46. Giaretti W. Aneuploidy mechanisms in human colorectal preneoplastic lesions and Barrett's esophagus. Is there a role for K-ras and p53 mutations? Anal Cell Pathol 1997; 15: 99-117 [PMID: 9413595]
47. Younes M, Lebovitz RM, Lechago LV, Lechago J. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 1993; 105: 1637-1642 [PMID: 8253340]
48. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969; 3: 87-97 [DOI: 10.1055/s-0028-1098086]
49. Yachida S, Saito D, Kozu T, Gotoda T, Inui T, Fujishiro M, Oda I, Okabayashi T, Kakugawa Y, Ono H, Kondo H. Endoscopically demonstrable esophageal changes after Helicobacter pylori eradication in patients with gastric disease. J Gastroenterol Hepatol 2001; 16: 1346-1352 [PMID: 11851831 DOI: 10.1046/j.1440-1746.2001.02628.x]
50. Nelsen EM, Kirihara Y, Takahashi N, Shi Q, Lewis JT, Namasivayam V, Buttar NS, Dunagan KT, Prasad GA. Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2012; 10: 728-734; quiz e61-62 [PMID: 22433923]